AGM Presentation and Address
Filed with ASX · · 15 pages · English
This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of
In the deck
Story so far
Earlier from Acrux
- Acrux receives $0.4m advance on FY26 R&D Tax Incentive
- Received $3.04m RDTI rebate for FY25
- Appendix 4E and Full Year Statutory Accounts FY25
- Licensing partnership in Saudi Arabia for Dapsone 5%, Gel
- Receipt of second advance for FY25 R&D Tax Incentive
Later from Acrux
- Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Acrux receives $0.55m advance on FY26 R&D Tax Incentive
- Acrux strategy focuses on Female Testosterone for low libido
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux